Latest Rhinitis Stories

2008-11-06 11:17:34

LONDON and NEW YORK, Nov. 6 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on novel, anti-inflammatory drugs, today announced positive data from its ICH compliant Phase II equivalent multi-center study of MRX-4 (n=105) in patients suffering from allergic rhinitis.

2008-11-05 09:00:34

WALTHAM, Mass., Nov. 5 /PRNewswire/ -- Decision Resources one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that physicians and patients respond to different marketing messages when considering which asthma medicine to use.

2008-10-30 12:00:21

Morria Biopharmaceuticals, a developer of novel, anti-inflammatory drugs, has announced the preliminary results from its recently completed Phase II equivalent study of MRX-4, in a nasal aerosol formulation, in 105 patients suffering from allergic rhinitis.

2008-10-28 06:00:28

Meda, a specialty pharma company, has announced that its new drug application for a newly formulated higher strength azelastine nasal spray has now been accepted by the FDA as complete for substantive review after initial evaluation.

2008-10-27 15:00:00

ANTONY, France, October 27 /PRNewswire-FirstCall/ -- Stallergenes has just obtained authorization (IND(1)) from the FDA for immediately launching a phase III clinical trial in the United States with Oralair(R) Grasses in the treatment of allergic rhinoconjunctivitis to grass pollens in adults.

2008-10-17 03:00:16

Regulatory News: Meda AB (STO:MEDAA): The U.S. Food and Drug Administration (FDA) has approved Astepro - the new formulation of Astelin. Astepro Nasal Spray is an improvement over the marketed Astelin Nasal Spray and is better tolerated by patients using the new spray.

2008-10-06 21:00:11

Thai researchers suggest patients on allergy medicine are better served when they adjust their dose to symptoms.

2008-10-03 09:00:38

Circassia, a specialty biopharmaceutical company, has started a further Phase II clinical study of its ToleroMune technology in the field of cat allergy.

2008-10-02 06:00:34

OXFORD, England, October 2 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on the fields of allergy and critical care, today announced the start of a further phase II clinical study of its ToleroMune(R) technology in the field of cat allergy.

Word of the Day
  • Emitting flashes of light; glittering.
The word 'coruscant' comes from a Latin word meaning 'to flash' or 'to sparkle'.